Ovarian Cancer Trial, Not Yet Recruiting NCT07311122 Sponsor: Gangnam Severance Hospital Condition: Ovarian Cancer
Back to Ovarian Cancer

Ovarian Cancer Trial, Not Yet Recruiting

NCT07311122
Not Yet Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with breast cancer that was confirmed through a laboratory tissue test
  • You were 50 years old or younger when you were first diagnosed
  • You were still having periods (or had hormone levels showing you were premenopausal) at the time of diagnosis
  • You had surgery aimed at removing all the cancer (curative surgery) between January 2012 and December 2021
  • Your tumor was within a certain size range (not too advanced) based on what was found during surgery (confirm with trial site)
  • The cancer had spread to no lymph nodes, or only a small number of nearby lymph nodes, at the time of surgery
  • Your cancer tested positive for hormone receptors (estrogen and/or progesterone) on a lab test
  • Your cancer tested negative for a protein called HER2 on standard lab tests
  • You had a specific genetic test called Oncotype DX® done on your tumor, and your score fell within a particular range depending on whether your lymph nodes were affected (confirm with trial site)

Who may not be able to join:

  • Your cancer had already spread to other parts of your body at the time of diagnosis
  • You were already past menopause at the time of diagnosis (for example, due to having both ovaries removed before your breast cancer diagnosis, or based on hormone level results)
  • Your cancer tested negative for hormone receptors, or tested positive for HER2
  • There is not enough clear information available about what treatments you received after surgery
  • You had a different type of cancer that was treated before your breast cancer diagnosis — exceptions may be made for thyroid cancer or certain types of skin cancer
  • You had cancer in both breasts at the same time
  • You received chemotherapy, hormone therapy, or other systemic treatments before your surgery

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Not Applicable
Sponsor
Gangnam Severance Hospital
Registry
ClinicalTrials.gov
Start date
1 January 2026
Est. completion
31 December 2027

Primary endpoints

invasive disease-free survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov